Q-omics provides the consensus-scored MRPS17 profile across patient tissues and cancer cell-line models. MRPS17 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPS17 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, MRPS17 RNA expression shows 18,741 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, LIHC, and ACC as cancer lineages where MRPS17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS17 survival associations across molecular data types. MRPS17 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS17 RNA expression–survival associations across cancer types. High MRPS17 expression shows unfavorable associations in UVM, KICH, LGG, HNSC, LIHC and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPS17 RNA expression.
This table summarizes MRPS17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS17 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, STAD and COAD. The LIHC box plot shows higher MRPS17 RNA expression in tumor versus normal tissue (log2 FC = +1.230, t-test p < 0.001).
This table shows molecular features associated with MRPS17 in patient tissues and cancer cell lines. In patient samples, MRPS17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
